MECP2 and prostate carcinoma: The results indicated that MeCP2 expression was higher in the brain, esophageal, kidney, leukemia, lung, and lymphoma cancer, compared to the normal tissues, and lower expression in other different types of cancers, such as brain, breast leukemia, ovarian, and prostate cancers (Fig. 2A).